Aug 07, 2025
Immunic, Inc. Reports Second Quarter 2025 Financial Results and Provides Corporate Update
Jun 24, 2025
Immunic Reports New, Positive Long-Term Open-Label Extension Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis
Jun 02, 2025
Immunic to Participate in Investor, Scientific and Industry Conferences in June
May 28, 2025
Immunic, Inc. Announces Proposed Public Offering
Apr 10, 2025
Immunic, Inc. Announces Closing of $5.1 Million Registered Direct Offering, Led by Aberdeen Investments
Apr 09, 2025
Immunic, Inc. Announces Pricing of $5.1 Million Registered Direct Offering, Led by Aberdeen Investments
Apr 01, 2025
Immunic, Inc. to Participate in Scientific and Industry Conferences in April
Mar 03, 2025
Immunic to Participate in Scientific and Investor Conferences in March
Feb 26, 2025
Immunic Presents Key Vidofludimus Calcium Data at the ACTRIMS Forum 2025, Highlighting Its Potential in Multiple Sclerosis
Oct 31, 2024
Immunic, Inc. to Announce Financial Results for the Third Quarter Ended September 30, 2024, and Provide Corporate Update
Sep 04, 2024
Immunic Announces First Patient Enrolled in Investigator-Sponsored Phase 2 Clinical Trial of Vidofludimus Calcium in Patients with Post COVID Syndrome
Aug 28, 2024
Immunic to Host Multiple Sclerosis R&D Day and Participate in Scientific and Investor Conferences in September
Aug 01, 2024
Immunic, Inc. to Announce Financial Results for the Second Quarter Ended June 30, 2024, and Provide Corporate Update
May 28, 2024
Immunic to Participate in Industry and Scientific Conferences in June
May 08, 2024
Immunic, Inc. Reports First Quarter 2024 Financial Results and Provides Corporate Update
May 06, 2024
Immunic to Participate in Investor and Scientific Conferences in May
May 01, 2024
Immunic, Inc. to Announce Financial Results for the First Quarter Ended March 31, 2024, and Provide Corporate Update
Apr 04, 2024
Immunic to Host MS R&D Day and Participate in Investor Conferences in April
Mar 07, 2024
Immunic to Participate in Investor and Scientific Conferences in March
Feb 29, 2024
Immunic Presents Data From Phase 2 CALLIPER and CALVID-1 Trials of Vidofludimus Calcium at the ACTRIMS Forum 2024